Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.
- Author:
Daisuke ENDO
1
;
Yukiharu TODO
;
Kazuhira OKAMOTO
;
Shinichiro MINOBE
;
Hidenori KATO
;
Noriaki NISHIYAMA
Author Information
- Publication Type:Original Article
- Keywords: Brachytherapy; Chemoradiotherapy; Proportional Hazards Models; Retrospective Studies; Uterine Cervical Neoplasms
- MeSH: Adult; Aged; Aged, 80 and over; Brachytherapy/adverse effects/methods; Chemoradiotherapy/adverse effects/*methods; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms/diagnosis/pathology/*therapy
- From:Journal of Gynecologic Oncology 2015;26(1):12-18
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Concurrent chemoradiotherapy (CCRT) is the primary treatment for locally advanced cervical cancer. We studied prognostic factors for patients treated with CCRT. METHODS: We retrospectively reviewed records of 85 consecutive patients with cervical cancer who were treated with CCRT between 2002 and 2011, with external beam radiation therapy, intracavitary brachytherapy, and platinum-based chemotherapy. Survival data were analyzed with Kaplan-Meier methods and Cox proportional hazard models. RESULTS: Of the 85 patients, 69 patients (81%) had International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease; 25 patients (29%) had pelvic lymph node enlargement (based on magnetic resonance imaging), and 64 patients (75%) achieved clinical remission following treatment. Median maximum tumor diameter was 5.5 cm. The 3- and 5-year overall survival rates were 60.3% and 55.5%, respectively. Cox regression analysis showed tumor diameter >6 cm (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.2 to 4.6), pelvic lymph node enlargement (HR, 2.2; 95% CI, 1.1 to 4.5), and distant metastasis (HR, 10.0; 95% CI, 3.7 to 27.0) were significantly and independently related to poor outcomes. CONCLUSION: New treatment strategies should be considered for locally advanced cervical cancers with tumors >6 cm and radiologically enlarged pelvic lymph nodes.
